Giacardy-Paty M, Soubrouillard C, Blin O
Laboratoire de Pharmacologie Médicale et Clinique et CPCET, Hôpital de la Timone, Marseille, France.
Encephale. 1995 Jun;21 Spec No 3:3-8.
The dopaminergic hypothesis in schizophrenia has progressively shifted to a bipolar hypothesis. Furthermore, there are numerous interactions between dopaminergic systems and other neurotransmission systems. Therefore, several pharmacological approaches are possible either through the specific antagonism of different dopaminergic receptors subclasses, partial dopaminergic agonists or indirect modulation or through the combined blockade of dopaminergic and serotoninergic, cholinergic or adrenergic receptors. The challenge today is to link a given clinical effect to one specific pharmacological property.
精神分裂症中的多巴胺能假说已逐渐转向双相假说。此外,多巴胺能系统与其他神经传递系统之间存在众多相互作用。因此,有几种药理学方法是可行的,要么通过对不同多巴胺能受体亚类的特异性拮抗、部分多巴胺能激动剂或间接调节,要么通过对多巴胺能和5-羟色胺能、胆碱能或肾上腺素能受体的联合阻断。如今的挑战是将特定的临床效果与一种特定的药理学特性联系起来。